Company intelligence / Profile preview

NanoNeurosciences

Alachua / Gainesville area*, Florida, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Preclinical

Overview

NanoNeurosciences is developing a nanotechnology-based platform using self-organizing lipopeptide sequences to deliver neuroactive molecules in a controlled and sustained manner. Their lead program targets primary open-angle glaucoma and other degenerative eye diseases. The company is currently at the pre-clinical stage; no published clinical results are available yet.[1][2][3]

Therapeutic areas: Ophthalmology
Modalities: LipopeptidesNanostructures for drug deliveryNeuropeptidesmRNA delivery systems[1][2][3]
Industry: Biotech

Drug pipeline

1 asset

NC134

Preclinical

Partnerships

UF Innovate | Sid Martin Biotech Accelerator client company affiliation/partnerships with University of Florida innovation ecosystem[4]

Beyond the preview

Go deeper on NanoNeurosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NanoNeurosciences.

Explore the full profile